Novartis and Medicines for Malaria Venture form new partnership

 | Source: Novartis Pharma AG Novartis Pharma AG

 -- MEDIA ADVISORY --
 
Novartis and Medicines for Malaria Venture (MMV) to form new partnership to improve access to breakthrough malaria drug for children
 
Who:     
- Dr. Daniel Vasella, Chairman and CEO of Novartis
- Dr. Christopher Hentschel, CEO of MMV
- Prof. Nicholas White, Faculty of Tropical Medicine,
   Mahidol University, Thailand
 
What:    Press conference to announce the signing of an agreement to jointly develop a pediatric formulation of Coartem®, a breakthrough in treatment-resistant malaria.
 
Where:  Novartis International AG
Werk St. Johann, WSJ-200-305
Lichtstrasse 35
4002 Basel
Switzerland
 
When:    10 November 2003, 10:45 am - 11:30 am.
 
 
Conference Call:
 
Type:         
Dial-In Conference Call in English
Presentation followed by Q&A session
 
Dial-In number:      +41 91 610 5600
 
Playback:  
The playback will be available 1 hour after the
conference call for 48 hrs.
Participants requesting the Digital Playback will be
dialing:
                   +41 91 612 4330 (in Europe and Africa)
                   +44 207 866 4300 (in UK)
                   +  1 877 344 7529 (in USA)
                   and will be asked to enter the ID 640 followed by the # sign
 
# # #